Evofem Biosciences Inc. and Pharma 1 Drug Store Submit PHEXXI for Regulatory Approval in UAE, Targeting Q1 2026 Launch

Reuters

06-23

Evofem Biosciences Inc. and Pharma 1 Drug Store Submit PHEXXI for Regulatory Approval in UAE, Targeting Q1 2026 Launch

Evofem Biosciences Inc. has announced that Pharma 1 Drug Store LLC, a private Emirati health care company, has filed an application with the United Arab Emirates $(UAE)$ Ministry of Health and Prevention seeking approval to commercialize PHEXXI®, Evofem's FDA-approved hormone-free contraceptive. This marks a significant step towards the international expansion of PHEXXI, with a targeted commercial launch in the UAE set for the first quarter of 2026. Following regulatory approval, Pharma 1 plans to place a launch quantity order for PHEXXI in July 2025. This collaboration highlights the growing demand for hormone-free contraception in the UAE and surrounding regions, and supports Evofem's strategy to diversify its revenue stream outside the U.S.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA15420) on June 23, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2545414620"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2545414620\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2545414620?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-23 20:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545414620","market":"us","top_or_hot":-1,"title":"Evofem Biosciences Inc. and Pharma 1 Drug Store Submit PHEXXI for Regulatory Approval in UAE, Targeting Q1 2026 Launch","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Evofem Biosciences Inc. and Pharma 1 Drug Store Submit PHEXXI for Regulatory Approval in UAE, Targeting Q1 2026 Launch\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Evofem Biosciences Inc. has announced that Pharma 1 Drug Store LLC, a private Emirati health care company, has filed an application with the United Arab Emirates <a href=\"https://laohu8.com/S/UAE\">$(UAE)$</a> Ministry of Health and Prevention seeking approval to commercialize PHEXXI®, Evofem's FDA-approved hormone-free contraceptive. This marks a significant step towards the international expansion of PHEXXI, with a targeted commercial launch in the UAE set for the first quarter of 2026. Following regulatory approval, Pharma 1 plans to place a launch quantity order for PHEXXI in July 2025. This collaboration highlights the growing demand for hormone-free contraception in the UAE and surrounding regions, and supports Evofem's strategy to diversify its revenue stream outside the U.S.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA15420) on June 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Evofem Biosciences Inc. and Pharma 1 Drug Store Submit PHEXXI for Regulatory Approval in UAE, Targeting Q1 2026 Launch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEvofem Biosciences Inc. and Pharma 1 Drug Store Submit PHEXXI for Regulatory Approval in UAE, Targeting Q1 2026 Launch\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-23 20:47</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Evofem Biosciences Inc. and Pharma 1 Drug Store Submit PHEXXI for Regulatory Approval in UAE, Targeting Q1 2026 Launch\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Evofem Biosciences Inc. has announced that Pharma 1 Drug Store LLC, a private Emirati health care company, has filed an application with the United Arab Emirates <a href=\"https://laohu8.com/S/UAE\">$(UAE)$</a> Ministry of Health and Prevention seeking approval to commercialize PHEXXI®, Evofem's FDA-approved hormone-free contraceptive. This marks a significant step towards the international expansion of PHEXXI, with a targeted commercial launch in the UAE set for the first quarter of 2026. Following regulatory approval, Pharma 1 plans to place a launch quantity order for PHEXXI in July 2025. This collaboration highlights the growing demand for hormone-free contraception in the UAE and surrounding regions, and supports Evofem's strategy to diversify its revenue stream outside the U.S.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA15420) on June 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nNDL8d30mD:1","article_id":"2545414620","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545414620","pubTimestamp":1750682845,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Evofem Biosciences Inc. has announced that Pharma 1 Drug Store LLC, a private Emirati health care company, has filed an application with the United Arab Emirates  Ministry of Health and Prevention seeking approval to commercialize PHEXXI, Evofem's FDA-approved hormone-free contraceptive. This marks a significant step towards the international expansion of PHEXXI, with a targeted commercial launch in the UAE set for the first quarter of 2026. Following regulatory approval, Pharma 1 plans to place a launch quantity order for PHEXXI in July 2025. This collaboration highlights the growing demand for hormone-free contraception in the UAE and surrounding regions, and supports Evofem's strategy to diversify its revenue stream outside the U.S.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpr","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","EVFM":"Evofem Biosciences, Inc.","BK4584":"避孕概念"},"translate_title":"Evofem Biosciences Inc.和Pharma 1药店向阿联酋监管部门提交PHEXXI，计划于2026年第一季度上市","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EVFM":0.9},"content_text":"Evofem Biosciences Inc. and Pharma 1 Drug Store Submit PHEXXI for Regulatory Approval in UAE, Targeting Q1 2026 Launch\n    \n\n        Evofem Biosciences Inc. has announced that Pharma 1 Drug Store LLC, a private Emirati health care company, has filed an application with the United Arab Emirates $(UAE)$ Ministry of Health and Prevention seeking approval to commercialize PHEXXI®, Evofem's FDA-approved hormone-free contraceptive. This marks a significant step towards the international expansion of PHEXXI, with a targeted commercial launch in the UAE set for the first quarter of 2026. Following regulatory approval, Pharma 1 plans to place a launch quantity order for PHEXXI in July 2025. This collaboration highlights the growing demand for hormone-free contraception in the UAE and surrounding regions, and supports Evofem's strategy to diversify its revenue stream outside the U.S.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA15420) on June 23, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}